Thank you for subscribing!

Bringing High-Quality Hemp Products (And More) to Market

A Vertically-Integrated Investment that Expands Science for Industrial Hemp

Global Sciences is a vertically integrated hemp-based CBD producer, extractor, and branding investment vehicle which currently owns multiple product categories through multiple subsidiaries, including, Aethics, Cannaoil, Strasburg Pharms Certified, Resinosa, and Pure BioPlastics. The company began as a specialist in a wide range of CBD products, setting new standards of both quality and productivity. Through their mission to provide pure and natural products to the modern consumer new opportunities and investments sparked wider involvement in the wellness field.

5 Reasons to Get Excited About CBD Global

  • Expansive Distribution – Well established distribution network delivering high-quality products both in retail and ecommerce formats nationwide.
  • Viable Land Holdings Wholly owned subsidiary, Strasburg Pharms acquired 179 contiguous acres of farmable land with additional acres available for future expansion.
  • Massive Market The industrial hemp market is growing rapidly from its $4.6 billion value in 2019 to reach a projected $26.6 billion by 2025.
  • Expert Team Run by an allstar management team and highly skilled distribution and sales managers that have expertise in large scale direct store delivery.
  • Great Endorsements – Owns a CBD product line, Aethics, that has numerous pro athlete endorsements.
  • Continuous Growth – After establishing itself as a leader in the CBD market, the most recent acquisition of BioPlastics Inc. secures Global Science’s position as a multifaceted company.

A Name Change Targeting Growth

If Global Sciences sounds familiar but you’re not sure why, it’s because the company had actually established itself as CBD Global Sciences prior to 2022. Its growth and success called for a broader reach, however, and CBD was dropped from the name.

This pivot came as a result of discovering new opportunities that could create value for shareholders, no longer limiting product development to the CBD market alone.

“The name change will not impact the Company’s ability to increase revenues and profitability within the CBD and distribution industries, it will enhance its ability to better define itself as it explores other areas in the field of wellness sciences,” the company wrote.

Simply put, Global Sciences is now taking its piece of an even larger pie, pivoting from operation in a $3.5 billion industry in 2021 to one projected to reach $26.6 billion by 2025.

“In the ever-changing industry of CBD the team at Global Sciences has become accustomed to quickly pivoting to provide better value to its customers and shareholders,” said CEO Brad Wyatt. “This change is the beginning of more exciting news that will be presented in the near term. We are still very active in the CBD landscape and presenting wins for our company with lower cost manufacturing and more points of distribution which will translate into increased revenues and improved profitability. We are very excited about 2022 and beyond for our company and its shareholders.”

The Case for Investing In Renewable Plastics

Global Science’s first move after officially filing for its name change was announcing the acquisition of 100% of BioPlastics Inc, a Colorado based manufacturer of reusable, recyclable, and biodegradable plastics.

As a developer of multiple consumer products, the acquisition could enable Global Sciences to apply a sustainable approach to the distribution and packaging of products for its subsidiaries. But it also grants Global Sciences access to technology that will create bioplastics from non-food biomass, which includes hemp. Pure BioPlastics was established to supply bio-based solutions to our dependence on oil-based plastics, swapping them out with more sustainable bio-based plastics instead. One of the company’s breakthroughs include the development of its continuous countercurrent reactor technology (CCR), which can now support a wide variety of “Designer Biodegradable Products,” such as straws, lids, and even plastic parts of cars and aircrafts.

Bioplastics had a global market value of approximately $7.6 billion in 2021 and is expected to nearly double by 2028 to $15.5 billion.

Dog the Bounty Hunter

In January, Global Sciences launched the new product line “Dog Unleashed CBD” in partnership with Dog the Bounty Hunter. Duane “Dog” Chapman has starred in many reality tv shows about his bounty hunting experiences and personal life. Dog currently has a spin-off entitled Dog’s Most Wanted in production at WGN America and his next project, Dog’s Unleashed, is set to premiere in 2021 on the streaming site Unleashed.

His past shows have set viewership records on A&E, WGN and CMT, but Dog’s Unleashed is expected to surpass even those. Dog will be doing many interviews on prominent talk shows about both his series and Dog Unleashed CBD.

Dog struggled for years to find a way to ease the physical and mental pain that came with his job as a bounty hunter. He was always wary of over-the-counter or prescription painkillers, so he was thrilled when he found CBD.

Eventually he decided to create his own brand, but he wanted to work with a company that he knew he could count on to always deliver quality. He chose to partner with Global Sciences because they completely control the product with stringent chain of custody requirements. They organically grow hemp and use a cold fusion process to extract the cannabinoids, leading to a full spectrum and pure CBD product. Dog has stated that


The CBD infused products they provide are by far the best that I’ve tried over the years…The team at CBD Global Sciences is the team I chose to create my product and that is because I know and trust them.


Dog Unleashed CBD consists of a robust line of CBD products, aimed at addressing many bodily pains with a natural approach. The product launch will coincide with the release of Dog’s new show, streaming on the Unleashed internet platform.

The initial product line will offer 12 different SKUs in three different strengths 1000MG, 2000MG and 3500MG– all of which are infused with a lab tested, full spectrum CBD oil. The offerings will also include both lotions and salves. All products meet established state and federal requirements of no more than 0.3% delta-9-tetrahydrocannabinol and can be sold in all 50 states. Global Sciences will expand the product offerings over the next two quarters in 2021 including CBD infused confectionary products and a hydration line featuring multi flavored energy drinks.

Learn more about Dog and Dog Unleashed CBD here.

Product Categories



The Aethics brand was born from the need for a trusted source for CBD (cannabidiol) sports wellness products. Global Sciences founders saw a leadership void in this fast growing sports category, and a unique opportunity to create a brand that concentrates on individuals living active lifestyles.

Consumers are requesting natural, non-addicting solutions for pain relief, inflammation, insomnia, anxiety, nausea and related common and chronic ailments. The Aethics brand presents an informative, ethical destination for the athlete that is looking for safe alternatives in caring for their body and mind.

Aethics boasts 3 topical CBD creams, 5 CBD infused drinks and 3 CBD performance drops.
@TeamAethics |


The CannaOil brand was created in 2016 to provide the highest quality CBD derived from hemp products on the market.

The hemp oil is obtained using a super cold extraction process on local Colorado plants, maximizing productions and quality. All hemp used to create the products is grown locally at Strasburg Pharms, which is pesticide free and only uses natural additives to craft the most effective product on the market.

The Process

  • The Colorado hemp plants are grown with all natural Colorado water, soil, sun and nutrients, and NEVER sprayed with pesticides or chemicals.
  • The genetics are hand selected and maintained to present the best cannabinoid spectrum with extremely high CBD and below 0.3% THC results.
  • The hot summer days and cool Colorado nights enable a perfect environment for hemp cultivation.
  • At 5280 feet above sea level, the farm enables more potent UV rays presenting the perfect state for the plant’s natural chemical reactions to facilitate maximum plant potency and growth.
  • The plants are harvested and cured by hand, on site, prior to going through a cold fusion extraction process.

Strasburg Pharms Certified

Strasburg Pharms Certified is a stamp of CBD Hemp quality placed on the company’s products, and awarded to worthy third party companies throughout the US looking to develop their own brands and white labeled CBD products.

Certification ensures the following:

    • Seeds are hemp from the state of Colorado.
    • All seeds are tested for the highest potency of hemp plants with the best terpene profile available.
    • The growing process exceeds all state and federal organic growing requirements, while using manure and fresh well water from the Rocky Mountains.
    • All pests are controlled organically and without chemicals.
    • Biodegradable mulch is used to protect from additional waste hazards during harvest.
    • Hydration process is proven to conserve 80% of water in an effort to help the environment.
    • Crop is hand cut and flash dried to preserve tricons for superior product potency.
    • An in-house Cold Fusion process is used to wash the plants with food-grade ethanol so the customer receives exactly what is listed on the product label.


The Market for Hemp and CBD

So what is hemp and CBD, and where’s the market for it? While there are many common misconceptions about the nature of hemp and CBD, you’d have to be living under a rock to think that there isn’t a huge market for these products.

Hemp is a part of cannabis, a type of flower in the Cannabaceae family, but it is not used to get you high like one hearing “cannabis” might think. THC (tetrahydrocannabinol) is a cannabinoid, or chemical, found in cannabis and is responsible for the “high” effects associated with the cannabis plant. To be legally labeled as hemp, there must be .3% or less THC in the product.

Most industrial hemp doesn’t produce many buds, and almost all the THC in the cannabis plant is formed in resin glands on the buds and flowers. Since industrial hemp isn’t grown to cultivate said buds, it lacks the main components that would get someone high. Industrial hemp also has higher concentrations of cannabidiol (CBD) which actually lessens the psychoactive effects of THC.

While the health benefits of the CBD continue to be explored, the World Health Organization has stated that CBD presents no evidence of abuse or dependence potential. The CBD retail industry is already booming, with a plethora of products marketed as treatments for chronic pain, anxiety, depression, and more. However, it seems the market is on the cusp of another swell.

Leading cannabis researchers BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will exceed $20 billion by 2024. This is a slight increase from the recent estimation of $15 billion by 2025 by New York-based investment bank Cowen & Co.

BDS analytics also predicted a CBD growth rate of 49% across all distribution channels by 2024. There’s already a significant market for CBD products and it’s only going to get larger. As it continues to expand, so does the need for the most pure, full spectrum CBD possible, which CBD Global is in the perfect position to capitalize on.

Strasburg Pharms Grows On

Strasburg Pharms is a wholly owned subsidiary of Global Sciences and controls approximately 179 contiguous acres of farmable land through lease and purchase. The company also has the opportunity to purchase up to an additional 3,485 acres contiguous to its current 179 acres in Strasburg, Colorado.

The leaders behind Strasburg Pharms want to bring organically grown and genetically beneficial hemp to market in the most economical way possible. With more than 60 years of agricultural experience on their team, they aim to provide the highest quality hemp in their sector.

Industrial hemp can be genetically bred to produce high CBD potency and low THC potency. To be clear, CBD is a non-psychoactive cannabinoid, so it can be used without gaining the feelings of lethargy and/or dysphoria. CBD doesn’t make you “high,” but it does offer many healing and calming benefits that consumers rely on.

All the farms cannabidiol comes from organically grown, lab extracted and tested, industrial hemp.Their plants are hand picked to produce full spectrum CBD with maximum potency and less than or equal to .3% THC. They never use chemicals or pesticides in their completely all-natural approach, regulated by the Department of Agriculture.

Strasburg Pharms also uses a cold fusion extraction process, where the terpenes and cannabinoids are sealed with super cold temperatures. It’s one of the most natural and effective ways to extract the pure oils from the plant matter. All of this combined means that Strasburg Pharms can produce massive and growing quantities of high potency and quality CBD.

Strasburg Pharms


Past Press Releases

Management Team

CBD Global has secured a world-class team of experts with deep experience across a broad range of industries, and a proven track record of building brands and businesses

Senior Leadership



Chief Executive Officer and President

Mr. Wyatt is the cofounder/CEO of CBD Global as well as Strasburg Pharms, SMBT, and CannaOil, which are all wholly owned subsidiaries of CBD Global.
Professional Background includes executive positions with Federal Mogul, Sears Roebuck, and the Target Corporation.
Founder of MAC5 Mortgage Inc. which operates in 6 states and employs over 100 people.




Scott Darnell is the Marketing Manager for CBD Global.
He is responsible for linking the innovations of the company’s product team to the customer-focused operations of the business, thus building the company’s global brand, creating consumer awareness and advocacy, and driving customer preference.



Chief Operating Officer

Mr. Dooley co-founded MAC5 Mortgage Inc. with Brad Wyatt in 2006.
Mr. Dooley holds a bachelor’s degree in Biology and brings to the team a breadth of knowledge and experience in management and startups.




Operations Lead

Mr. Wyatt is currently the Supply Chain and Logistics Consultant with CBD Global.
Prior to this role, Jake was an expert in the supply chain area with various firms including Gencoa, FEDEX, and Sears Roebuck.
Mr. Wyatt holds a M.S in Transportation Management from Florida Institute of Technology and a degree in business administration from University of Tennessee.



Chief Financial Officer

Alexander McAulay CPA, CA is an experienced public company CFO.
Alex founded the successful Naked Brand Group Inc. (NASDAQ:NAKD) and led the company as its COO and CFO.
Alex is currently the CFO of Marifil Mines Limited (TSX-V:MFM), GreenStar Biosciences Corp. (CSE:GSTAR) and is the owner of a licensed accounting practice, ACM Management Inc., providing CFO advisory services to public companies.


Board of Directors












Quick Bits-Investment Highlights

  1. Allstar management team that’s highly skilled in distribution and sales.
  2. Tackling a $2.8 billion industry with superior, high quality, and natural products.
  3. Extensive and growing list of distribution agreements with multiple large-scale brands.




Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - CBD Global Sciences Inc. (CBDNF)
  • Amount & Form of Compensation - $400,000.00 in Restricted Common Stock
  • Who Paid for the Campaign & Position with Company if any - CBD Global Sciences Inc. (CBDNF)
  • Period of Campaign - 7/27/2020 - 7/27/2021
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - CBD Global Sciences Inc. (CBDNF)
  • Number of Shares We or our Affiliates Hold - 2,666,666
  • Price We Paid Per Share - $0
  • Date Issued - 7/27/2021

Related Post

Register to Download Presentation

Go to website
Go to top